Inogen (INGN) Stock Price
Inogen Price
Over the last 14 years Inogen grew revenue by 19.0% annually, reaching 348.67 M USD. Earnings per share have grown at 109.7% per year over the last 6 years. For Inogen, the net margin of -6.5% is down versus -1.8% a few years ago. The consensus 12-month price target for Inogen is 13.26 USD, about 102.8% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 17% above its 52-week low.
Inogen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Inogen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Inogen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Inogen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Inogen Price |
|---|---|
| 7/10/2026 | 6.54 USD |
| 7/9/2026 | 6.53 USD |
| 7/8/2026 | 6.42 USD |
| 7/7/2026 | 6.54 USD |
| 7/6/2026 | 6.64 USD |
| 7/2/2026 | 6.60 USD |
| 7/1/2026 | 6.65 USD |
| 6/30/2026 | 6.45 USD |
| 6/29/2026 | 6.93 USD |
| 6/26/2026 | 6.94 USD |
| 6/25/2026 | 6.78 USD |
| 6/24/2026 | 6.76 USD |
| 6/23/2026 | 6.54 USD |
| 6/22/2026 | 6.36 USD |
| 6/18/2026 | 6.41 USD |
| 6/17/2026 | 6.37 USD |
| 6/16/2026 | 6.41 USD |
| 6/15/2026 | 6.46 USD |
| 6/12/2026 | 6.40 USD |
| 6/11/2026 | 6.30 USD |
| 6/10/2026 | 6.53 USD |
| 6/9/2026 | 6.35 USD |
| 6/8/2026 | 6.06 USD |
| 6/5/2026 | 6.41 USD |
| 6/4/2026 | 6.31 USD |
| 6/3/2026 | 5.98 USD |
| 6/2/2026 | 6.09 USD |
| 6/1/2026 | 6.09 USD |
| 5/29/2026 | 6.49 USD |
| 5/28/2026 | 6.54 USD |
| 5/27/2026 | 6.58 USD |
| 5/26/2026 | 6.58 USD |
| 5/22/2026 | 6.40 USD |
| 5/21/2026 | 6.41 USD |
| 5/20/2026 | 6.34 USD |
| 5/19/2026 | 6.45 USD |
| 5/18/2026 | 6.30 USD |
| 5/15/2026 | 6.38 USD |
| 5/14/2026 | 6.80 USD |
| 5/13/2026 | 6.81 USD |
| 5/12/2026 | 6.68 USD |
| 5/11/2026 | 6.62 USD |
| 5/8/2026 | 7.02 USD |
| 5/7/2026 | 7.19 USD |
| 5/6/2026 | 7.11 USD |
| 5/5/2026 | 7.05 USD |
| 5/4/2026 | 6.97 USD |
| 4/22/2026 | 7.15 USD |
| 4/21/2026 | 6.96 USD |
| 4/20/2026 | 6.95 USD |
| 4/17/2026 | 6.82 USD |
| 4/16/2026 | 6.59 USD |
| 4/15/2026 | 6.20 USD |
| 4/14/2026 | 6.34 USD |
| 4/13/2026 | 6.45 USD |
| 4/10/2026 | 6.33 USD |
| 4/9/2026 | 6.66 USD |
| 4/8/2026 | 6.67 USD |
| 4/7/2026 | 6.80 USD |
| 4/6/2026 | 6.36 USD |
| 4/2/2026 | 6.21 USD |
| 4/1/2026 | 6.27 USD |
| 3/31/2026 | 6.18 USD |
| 3/30/2026 | 6.11 USD |
| 3/27/2026 | 6.19 USD |
| 3/26/2026 | 6.51 USD |
| 3/25/2026 | 6.42 USD |
| 3/24/2026 | 6.32 USD |
| 3/23/2026 | 6.45 USD |
| 3/20/2026 | 6.10 USD |
| 3/19/2026 | 6.16 USD |
| 3/18/2026 | 6.16 USD |
| 3/17/2026 | 6.20 USD |
| 3/16/2026 | 6.13 USD |
| 3/13/2026 | 6.06 USD |
| 3/12/2026 | 6.10 USD |
| 3/11/2026 | 6.23 USD |
| 3/10/2026 | 6.22 USD |
| 3/9/2026 | 6.36 USD |
| 3/6/2026 | 6.47 USD |
| 3/5/2026 | 6.55 USD |
| 3/4/2026 | 6.31 USD |
| 3/3/2026 | 6.21 USD |
| 3/2/2026 | 6.18 USD |
| 2/27/2026 | 6.10 USD |
| 2/26/2026 | 5.92 USD |
| 2/25/2026 | 6.01 USD |
| 2/24/2026 | 5.84 USD |
| 2/23/2026 | 5.77 USD |
| 2/20/2026 | 5.79 USD |
| 2/19/2026 | 5.83 USD |
| 2/18/2026 | 5.83 USD |
| 2/17/2026 | 5.69 USD |
| 2/16/2026 | 5.69 USD |
| 2/13/2026 | 5.76 USD |
| 2/12/2026 | 5.76 USD |
| 2/11/2026 | 5.79 USD |
| 2/10/2026 | 6.13 USD |
| 2/9/2026 | 5.75 USD |
| 2/8/2026 | 5.59 USD |
| 2/6/2026 | 5.66 USD |
| 2/5/2026 | 5.66 USD |
| 2/4/2026 | 5.66 USD |
| 2/3/2026 | 5.84 USD |
| 2/2/2026 | 5.95 USD |
| 2/1/2026 | 6.00 USD |
| 1/30/2026 | 5.90 USD |
| 1/29/2026 | 5.90 USD |
| 1/28/2026 | 5.82 USD |
| 1/27/2026 | 5.86 USD |
| 1/26/2026 | 5.89 USD |
| 1/25/2026 | 6.01 USD |
| 1/23/2026 | 6.03 USD |
| 1/22/2026 | 6.03 USD |
| 1/21/2026 | 6.22 USD |
| 1/20/2026 | 6.36 USD |
| 1/19/2026 | 6.21 USD |
| 1/16/2026 | 6.25 USD |
| 1/15/2026 | 6.25 USD |
| 1/14/2026 | 6.45 USD |
| 1/13/2026 | 6.50 USD |
| 1/12/2026 | 6.22 USD |
| 1/11/2026 | 6.21 USD |
| 1/9/2026 | 7.03 USD |
| 1/8/2026 | 7.03 USD |
| 1/7/2026 | 7.22 USD |
| 1/6/2026 | 7.32 USD |
| 1/5/2026 | 6.79 USD |
| 1/4/2026 | 6.65 USD |
| 1/2/2026 | 6.63 USD |
| 1/1/2026 | 6.63 USD |
| 12/31/2025 | 6.72 USD |
| 12/30/2025 | 6.72 USD |
| 12/29/2025 | 6.72 USD |
| 12/28/2025 | 6.71 USD |
| 12/26/2025 | 6.80 USD |
| 12/25/2025 | 6.80 USD |
| 12/24/2025 | 6.67 USD |
| 12/23/2025 | 6.67 USD |
| 12/22/2025 | 6.68 USD |
| 12/21/2025 | 6.75 USD |
| 12/19/2025 | 6.71 USD |
| 12/18/2025 | 6.71 USD |
| 12/17/2025 | 6.83 USD |
| 12/16/2025 | 6.82 USD |
| 12/15/2025 | 6.81 USD |
| 12/14/2025 | 6.83 USD |
| 12/12/2025 | 7.06 USD |
| 12/11/2025 | 7.06 USD |
| 12/10/2025 | 7.02 USD |
| 12/9/2025 | 6.91 USD |
| 12/8/2025 | 6.72 USD |
| 12/7/2025 | 6.67 USD |
| 12/5/2025 | 6.94 USD |
| 12/4/2025 | 6.94 USD |
| 12/3/2025 | 6.99 USD |
| 12/2/2025 | 6.91 USD |
| 12/1/2025 | 6.74 USD |
| 11/30/2025 | 6.95 USD |
| 11/28/2025 | 7.08 USD |
| 11/27/2025 | 7.08 USD |
| 11/26/2025 | 7.12 USD |
| 11/25/2025 | 7.12 USD |
| 11/24/2025 | 7.09 USD |
| 11/23/2025 | 7.08 USD |
| 11/21/2025 | 6.88 USD |
| 11/20/2025 | 6.88 USD |
| 11/19/2025 | 6.59 USD |
| 11/18/2025 | 6.69 USD |
| 11/17/2025 | 6.85 USD |
| 11/16/2025 | 6.71 USD |
| 11/14/2025 | 6.90 USD |
| 11/13/2025 | 6.90 USD |
| 11/12/2025 | 6.88 USD |
| 11/11/2025 | 7.09 USD |
| 11/10/2025 | 6.99 USD |
| 11/9/2025 | 7.02 USD |
| 11/7/2025 | 6.99 USD |
| 11/6/2025 | 6.99 USD |
| 11/5/2025 | 7.03 USD |
| 11/4/2025 | 7.39 USD |
| 11/3/2025 | 8.06 USD |
| 11/2/2025 | 8.21 USD |
| 10/31/2025 | 8.24 USD |
| 10/30/2025 | 8.24 USD |
| 10/29/2025 | 8.17 USD |
| 10/28/2025 | 8.41 USD |
| 10/27/2025 | 8.53 USD |
| 10/26/2025 | 8.66 USD |
| 10/23/2025 | 8.77 USD |
| 10/22/2025 | 8.95 USD |
| 10/21/2025 | 8.85 USD |
| 10/20/2025 | 8.49 USD |
| 10/19/2025 | 8.58 USD |
| 10/16/2025 | 8.37 USD |
| 10/15/2025 | 8.51 USD |
| 10/14/2025 | 8.52 USD |
| 10/13/2025 | 8.37 USD |
| 10/12/2025 | 8.04 USD |
| 10/9/2025 | 8.16 USD |
| 10/8/2025 | 8.50 USD |
| 10/7/2025 | 8.69 USD |
| 10/6/2025 | 8.59 USD |
| 10/5/2025 | 8.43 USD |
| 10/2/2025 | 8.65 USD |
| 10/1/2025 | 8.53 USD |
| 9/30/2025 | 8.42 USD |
| 9/29/2025 | 8.17 USD |
| 9/28/2025 | 8.11 USD |
| 9/25/2025 | 8.22 USD |
| 9/24/2025 | 8.46 USD |
| 9/23/2025 | 8.43 USD |
| 9/22/2025 | 8.34 USD |
| 9/21/2025 | 8.66 USD |
| 9/18/2025 | 8.66 USD |
| 9/17/2025 | 8.79 USD |
| 9/16/2025 | 8.32 USD |
| 9/15/2025 | 8.50 USD |
| 9/14/2025 | 8.56 USD |
| 9/11/2025 | 8.54 USD |
| 9/10/2025 | 8.56 USD |
| 9/9/2025 | 8.32 USD |
| 9/8/2025 | 8.53 USD |
| 9/7/2025 | 8.45 USD |
| 9/4/2025 | 8.11 USD |
| 9/3/2025 | 8.12 USD |
| 9/2/2025 | 7.88 USD |
| 9/1/2025 | 8.10 USD |
| 8/28/2025 | 7.99 USD |
| 8/27/2025 | 7.96 USD |
| 8/26/2025 | 7.93 USD |
| 8/25/2025 | 7.99 USD |
| 8/24/2025 | 7.71 USD |
| 8/21/2025 | 7.75 USD |
| 8/20/2025 | 7.53 USD |
| 8/19/2025 | 7.37 USD |
| 8/18/2025 | 7.49 USD |
| 8/17/2025 | 7.55 USD |
| 8/14/2025 | 7.46 USD |
| 8/13/2025 | 7.67 USD |
| 8/12/2025 | 7.70 USD |
| 8/11/2025 | 7.58 USD |
| 8/10/2025 | 7.04 USD |
| 8/7/2025 | 6.48 USD |
| 8/6/2025 | 5.87 USD |
| 8/5/2025 | 6.30 USD |
| 8/4/2025 | 6.33 USD |
| 8/3/2025 | 6.54 USD |
| 7/31/2025 | 6.21 USD |
| 7/30/2025 | 6.31 USD |
| 7/29/2025 | 6.55 USD |
| 7/28/2025 | 6.60 USD |
| 7/27/2025 | 6.79 USD |
| 7/24/2025 | 6.80 USD |
| 7/23/2025 | 6.80 USD |
| 7/22/2025 | 6.73 USD |
| 7/21/2025 | 6.34 USD |
| 7/20/2025 | 6.29 USD |
| 7/17/2025 | 6.35 USD |
| 7/16/2025 | 6.68 USD |
| 7/15/2025 | 6.54 USD |
| 7/14/2025 | 6.55 USD |
| 7/13/2025 | 6.71 USD |
Inogen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Inogen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.00 | 75.00 | 112.00 | 159.00 | 202.00 | 249.00 | 358.00 | 361.00 | 308.00 | 358.00 | 377.00 | 315.00 | 335.00 | 348.00 | 376.00 | 405.00 |
| 60.00 | 56.25 | 49.33 | 41.96 | 27.04 | 23.27 | 43.78 | 0.84 | -14.68 | 16.23 | 5.31 | -16.45 | 6.35 | 3.88 | 8.05 | 7.71 |
| 47.92 | 52.00 | 49.11 | 47.80 | 48.02 | 48.59 | 49.72 | 47.37 | 44.81 | 49.16 | 40.58 | 40.00 | 45.97 | 44.25 | 44.25 | 44.25 |
| 23.00 | 39.00 | 55.00 | 76.00 | 97.00 | 121.00 | 178.00 | 171.00 | 138.00 | 176.00 | 153.00 | 126.00 | 154.00 | 154.00 | 166.39 | 179.22 |
| -5.00 | – | 5.00 | 11.00 | 20.00 | 21.00 | 51.00 | 21.00 | -5.00 | -6.00 | -83.00 | -102.00 | -35.00 | -22.00 | -22.00 | -15.00 |
| – | – | – | 120.00 | 81.82 | 5.00 | 142.86 | -58.82 | -123.81 | 20.00 | 1,283.33 | 22.89 | -65.69 | -37.14 | – | -31.82 |
| 18.00 | 18.00 | 18.00 | 20.70 | 21.10 | 21.90 | 22.50 | 22.20 | 22.00 | 22.50 | 22.90 | 23.18 | 23.65 | 26.60 | 26.60 | 26.60 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Inogen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Inogen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Inogen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Inogen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Inogen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Inogen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Inogen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Inogen business model & stock analysis
Inogen SWOT Analysis
Strengths
Inogen Inc possesses several strengths that contribute to its success:
1. Innovative Products: Inogen has a strong track record of developing and commercializing innovative oxygen therapy products, such as portable oxygen concentrators, which have revolutionized the industry.
2. Strong Brand Reputation: The company has built a reputable brand known for its reliability, quality, and customer satisfaction, leading to a loyal customer base.
3. Wide Market Presence: Inogen has established a strong market presence globally with its products available in multiple regions, allowing for diversified revenue streams.
Weaknesses
Inogen Inc also faces certain weaknesses that need to be addressed:
1. Dependence on Medicare Reimbursements: The company relies heavily on Medicare reimbursements for a significant portion of its revenue, which exposes it to changes in Medicare policies or reimbursement rates.
2. Limited Product Portfolio: Inogen's product range is focused on oxygen therapy, which makes the company vulnerable to market fluctuations and increases competition in the narrow segment.
3. Manufacturing Challenges: The company outsources its manufacturing, which presents potential risks related to quality control, supply chain disruptions, and increased costs.
Opportunities
Inogen Inc can leverage the following opportunities to further grow its business:
1. Aging Population: With the global population aging, there is an increasing demand for oxygen therapy products, offering potential for market expansion.
2. International Expansion: Inogen can explore untapped markets and expand its global footprint, diversifying its revenue sources and reducing dependence on specific regions.
3. Technological Advancements: The rapid advancement in technology opens up opportunities for the development of new and improved oxygen therapy products, allowing Inogen to stay ahead of the competition.
Threats
Inogen Inc should be wary of the following threats that could impact its business:
1. Regulatory Challenges: The company operates in a highly regulated industry, and any changes to government regulations or compliance requirements can significantly impact its operations and profitability.
2. Competitive Landscape: The oxygen therapy market is becoming increasingly competitive, with the entry of new players and existing competitors offering alternative solutions that may erode Inogen's market share.
3. Economic Factors: Economic downturns, fluctuations in exchange rates, or changes in healthcare spending can affect demand for Inogen's products and overall financial performance.
Inogen Segments
Inogen Revenue by Region
3 Years
5 Years
Max
Details
Inogen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Inogen historical P/E ratio, EBIT multiple, and P/S ratio
Inogen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Inogen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Inogen forecasts and price targets in July 2026
Analyst Price Targets 2026| Δ MOM Price Target | 0.00 % |
| Buy | 87.50 % (7) |
| Hold | 12.50 % (1) |
| Sell | 0.00 % (0) |
| 12M Price Target | 13.26 |
| Last Price | 6.54 |
| Currency | USD |
| 12M Return Potential | 102.75 % |
| LTM Return | 0 % |
Inogen Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/5/2026 | -0.29USD | 84.00 MUSD | 2026 Q1 |
| 4/30/2026 | -0.29USD | 84.00 MUSD | 2026 Q1 |
| 2/24/2026 | -0.36USD | 86.75 MUSD | 2025 Q4 |
| 8/7/2025 | -0.27USD | 92.41 MUSD | 2025 Q2 |
| 5/2/2024 | -0.67USD | 82.25 MUSD | 2024 Q1 |
| 2/21/2024 | -0.64USD | 78.53 MUSD | 2023 Q4 |
| 8/2/2023 | -0.37USD | 108.37 MUSD | 2023 Q2 |
| 5/3/2023 | -0.49USD | 95.57 MUSD | 2023 Q1 |
| 2/22/2023 | -0.59USD | 91.64 MUSD | 2022 Q4 |
| 11/2/2022 | -0.43USD | 99.19 MUSD | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Inogen stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Inogen shareholder structure
| % | Name |
|---|---|
9.87315% | |
5.69266% | |
5.34415% | |
4.75158% | |
4.07298% | |
3.66518% |
Inogen Executives and Management Board
Mr. Kevin Smith
(54)President, Chief Executive Officer, Director · since 2023
Mr. Michael Bourque
(62)Chief Financial Officer, Executive Vice President, Corporate Treasurer
Mr. Kevin Smith
(54)Executive Vice President - Business Development, General Counsel, Secretary
Mr. Gregoire Ramade
(55)Executive Vice President, Chief Commercial Officer
Ms. Elizabeth Mora
(64)Independent Chairman of the Board
Inogen Supply Chain
Inogen Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | -0.52 | 0.67 | 0.67 | 0.27 | 0.48 |
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | Apria, Inc. | 0 | -0.80 | -0.19 | -0.67 | — | |
| 2 | -0.31 | -0.80 | -0.43 | -0.65 | — | ||
| 3 | 0.45 | -0.51 | -0.46 | -0.40 | -0.16 | ||
| 4 | 0 | -0.62 | -0.07 | -0.57 | 0.04 | ||
| 5 | 0.14 | 0.86 | 0.74 | -0.02 | 0.22 |
Frequently asked questions about Inogen
The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.
Inogen stock
Inogen Peer Group
Inogen Ticker
Inogen FIGI
All fundamentals and in-depth analysis of Inogen
Our stock analysis for Inogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.